论文部分内容阅读
目的观察来得时(甘精胰岛素)联合二甲双胍、吡格列酮治疗2型糖尿病患者疗效及安全性。方法将口服降血糖药物血糖控制不佳的2型糖尿病患者随机分为两组,治疗组(来得时组)20例,对照组(诺和灵30R组)22例,来得时组给予睡前皮下注射1次,诺和灵30R组给予早晚餐前皮下注射各1次,两组均联合二甲双胍、吡格列酮,按照空腹血糖(FPG)调整胰岛素用量,治疗目标值FPG<7.0mmol/L,治疗时间12周。观察治疗前后空腹血糖、糖化血红蛋白(HbA1c)、体重变化、低血糖情况。结果治疗后两组患者的空腹血糖、餐后2h血糖均明显低于治疗前各组水平(P<0.05);诺和灵30R组血糖下降水平、BMI变化与来得时组无差异(P>0.05);来得时组低血糖发生率明显低于诺和灵30R组(P<0.01)。结论来得时和诺和灵30R均能使患者血糖达标,来得时组低血糖发生率明显低于诺和灵30R组,更安全、方便,患者依从性更高。
Objective To observe the efficacy and safety of the combination of metformin with metformin and pioglitazone in patients with type 2 diabetes mellitus. Methods 20 type 2 diabetic patients with poorly controlled blood glucose control were randomly divided into two groups: 20 cases in the treatment group (Bordener group) and 22 cases in the control group (Novolin 30R group) Injection twice a day, noradren 30R group was given once a day before breakfast and evening subcutaneous injection, metformin and pioglitazone in both groups were adjusted according to fasting blood glucose (FPG) dosage, the treatment target FPG <7.0mmol / L, treatment time 12 week. Fasting blood glucose, glycosylated hemoglobin (HbA1c), body weight changes and hypoglycemia were observed before and after treatment. Results After treatment, fasting blood glucose and postprandial blood glucose at 2h were significantly lower than those before treatment in both groups (P <0.05). There was no significant difference in the blood glucose level and BMI between the Norvuling 30R group and the control group (P> 0.05) ). The incidence of hypoglycemia in Bordeaux group was significantly lower than that of Novolin 30R group (P <0.01). Conclusions Both propranolol and norrerosine 30R can make patients achieve blood glucose level. The incidence of hypoglycemia in Lidexu group is significantly lower than that of Norvuling 30R group, which is safer, more convenient and patient compliance is higher.